Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors

뉴스 본문을 불러오고 있어요.

Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors | 웨이프 WAPE

Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors

기사 요약

관련 종목

댓글 —